Topical butyrate improves efficacy of 5‐ASA in refractory distal ulcerative colitis: results of a multicentre trial
2003/03/01 by P. Vernia, Piero Vernia, Vito Annese +15 · 222 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer #Clinical trial #Colitis #Colonoscopy #Colorectal cancer #Dermatology and Skin Diseases #Disease #Gastroenterology #Inflammatory Bowel Disease #Internal medicine #Medicine #Microscopic Colitis #Pathology #Placebo #Refractory (planetary science) #Sigmoidoscopy #Ulcerative colitis
paper · doi:10.1046/j.1365-2362.2003.01130.x
published in European Journal of Clinical Investigation 33(3), 244-248 (Wiley)
openalex publication_date 2003/03/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/05/21
Abstract
BACKGROUND: The treatment of distal ulcerative colitis, refractory to conventional 5-ASA/steroid treatment, is still a matter of debate. The present study aimed at confirming, with adequate statistical power, previous data indicating the usefulness of topical butyrate and 5-ASA in the treatment of this condition. DESIGN: Double-blind, placebo-controlled, multicentre study. A total of 51 patients with distal (< 65 cm) ulcerative colitis, refractory to topical 5-ASA/cortisone, were randomly allocated to receive topical 5-ASA 2 g and 80 mM L-1 sodium-butyrate bid (Group A; 24 patients) or 5-ASA 2 g and 80 mL saline bid (Group B; 27 patients) for 6 weeks. Sigmoidoscopy with biopsies, as well as clinical and laboratory evaluations, were carried out at enrollment and at the end of the trial. Primary endpoints: remission or marked improvement in endoscopic, histologic and clinical findings. RESULTS: Most parameters showed a significant improvement vs. baseline in both groups. Remission in six patients and improvement in 12 patients in Group A vs. one remission and 13 with improvement in Group B (P < 0.05). A significant difference in favour of Group A was recorded regarding the number of bowel movements (P < 0.01), urgency (P < 0.05) and the patients' self evaluation (P < 0.01). DISCUSSION: The combined treatment with topical butyrate and 5-ASA is significantly more effective than 5-ASA alone in the management of refractory distal colitis. Further improvements in the treatment of refractory distal ulcerative colitis may be feasible based on the identification of patient subgroups and the association of two or more active drugs. Butyrate may well be one of them.
Citations
Cited by
- Review article: the role of butyrate on colonic function
- Microbes in gastrointestinal health and disease. [europepmc]
- The bacterial fermentation product butyrate influences epithelial signaling via reactive oxygen species-mediated changes in cullin-1 neddylation. [europepmc]
- Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. [europepmc]
- The microbiome in infectious disease and inflammation. [europepmc]
- Regulation of inflammation by short chain fatty acids. [europepmc]
- The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. [europepmc]
- Intestinal commensal microbes as immune modulators. [europepmc]
- Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity. [europepmc]
- Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. [europepmc]
- The influence of early life nutrition on epigenetic regulatory mechanisms of the immune system. [europepmc]
- Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. [europepmc]
- Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. [europepmc]
- Butyrate upregulates endogenous host defense peptides to enhance disease resistance in piglets via histone deacetylase inhibition. [europepmc]
- Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. [europepmc]
- Interactions between Intestinal Microbiota and Host Immune Response in Inflammatory Bowel Disease. [europepmc]
- Implication of G Protein-Coupled Receptor 43 in Intestinal Inflammation: A Mini-Review. [europepmc]
- Gut microbial and metabolomic profiles after fecal microbiota transplantation in pediatric ulcerative colitis patients. [europepmc]
- Butyrate Does Not Protect Against Inflammation-induced Loss of Epithelial Barrier Function and Cytokine Production in Primary Cell Monolayers From Patients With Ulcerative Colitis. [europepmc]
- Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. [europepmc]
- Associations between Pro- and Anti-Inflammatory Gastro-Intestinal Microbiota, Diet, and Cognitive Functioning in Dutch Healthy Older Adults: The NU-AGE Study. [europepmc]
- The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. [europepmc]
- Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD. [europepmc]
- Oral Exposure to Polystyrene Microplastics of Mice on a Normal or High-Fat Diet and Intestinal and Metabolic Outcomes. [europepmc]
- Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications. [europepmc]
- Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial. [europepmc]
Related